drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous CD19-directed CAR T-cell therapy. Engineered patient T cells express a CAR (CD3ζ with costimulatory domains) that recognizes CD19; receptor engagement triggers CAR/TCR signaling, T-cell proliferation, and targeted cytotoxicity, eradicating CD19+ malignant B cells and producing on-target B-cell aplasia. Administered via intravenous autotransfusion for relapsed/refractory CD19+ B-ALL/B-lymphoblastic lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor (CD3ζ with costimulatory domains). Binding to CD19 activates the CAR, driving T-cell activation, expansion, and perforin/granzyme-mediated cytotoxicity to eliminate CD19-positive malignant B cells, with expected on-target B-cell aplasia.
drug_name
BIC-2219
nct_id_drug_ref
NCT06355739